Idoroenyi Amanam, Chidera Agu, Siddhi Korgaonkar, Abigail Hitchens, I-Hsuan Su, Svetlana Gavrilov, Derek Tang, Rohan C. Parikh, Keith Davis, Samantha Slaff. "Real-world hemoglobin (Hb) outcomes of patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving first-line (1L) luspatercept or 1L erythropoiesis-stimulating agents (ESAs) in the US." Blood, 2025. doi:10.1182/blood-2025-4620